NDA 018934 · Chartwell Rx
Methyldopa
Methyldopa · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 5, 1998 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Jun 29, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
10 Phase 3, 2 recruiting
FAERS reports
4,936
4,615 serious, 231 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2025.
INDICATION AND USAGE Hypertension.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 29, 1984 Original approval
2 products under this application
- METHYLDOPA · METHYLDOPA 250MG · TABLET, ORAL · Discontinued
- METHYLDOPA · METHYLDOPA 500MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Methyldopa" as an intervention, any sponsor and status, largest first.
- Community Level Interventions for Pre-eclampsiaPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01911494 · 87,500 participants (planned) · Start Sep 2013 · Primary completion May 2018
Drug: Magnesium Sulfate; Methyldopa · For: Pre-eclampsia; Hypertension, Pregnancy Induced
Sites: Belagavi, India; Maputo, Mozambique; Sagamu, Nigeria · 4 sites in all
- Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With NormoalbuminuriaPivotal-lookingStatus unknown
Hospital Authority, Hong KongGovernment (non-federal)
NCT01500590 · 1,400 participants · Start Nov 2011 · Primary completion Aug 2018
Drug: Renin-angiotensin system blockers; non-renin angiotensin system blockers · For: Diabetes; Hypertensive Disease
Sites: Hong Kong, China
- Oral Antihypertensive Regimens for Management of Hypertension in PregnancyPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT01912677 · 894 participants · Start Apr 2015 · Primary completion Sep 2017
Drug: Nifedipine; Labetalol and 1 more · For: Hypertension in Pregnancy; Preeclampsia
Sites: Nagpur, India · 2 sites in all
- Enhancement of Stroke Rehabilitation With LevodopaPivotal-lookingActive, not recruiting
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT03735901 · 610 participants · Start Jun 14, 2019 · Primary completion Aug 27, 2024
Drug: IMP Levodopa 100mg/Carbidopa 25mg; Matching placebo · For: Acute Stroke; Stroke Rehabilitation
Sites: Aarau, Switzerland; Bad Zurzach, Switzerland; Baden, Switzerland · 24 sites in all
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01568073 · 600 participants · Start Mar 2011 · Primary completion Nov 2013
Drug: BIA 9-1067; Entacapone and 4 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.Pivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01227655 · 427 participants · Start Mar 2011 · Primary completion Jul 2012
Drug: BIA 9-1067; Placebo and 3 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- Treatment of Orthostatic Hypotension in Autonomic FailurePivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223691 · 389 participants · Start Mar 2002 · Primary completion Jan 2017
Drug: Atomoxetine; Acarbose and 19 more · For: Autonomic Failure; Orthostatic Hypotension
Sites: Nashville, Tennessee
- Early Vascular Adjustments During Hypertensive PregnancyPivotal-lookingStatus unknown
Maastricht University Medical CenterAcademic, hospital or other
NCT02531490 · 368 participants (planned) · Start Jan 1, 2015 · Primary completion Feb 2023
Drug: Labetalol; Nifedipine and 1 more · For: Hypertension, Pregnancy-Induced; Pre-Eclampsia
Sites: Maastricht, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy1,364
- premature baby930
- maternal exposure during pregnancy838
- exposure during pregnancy698
- premature delivery584
- low birth weight baby389
- drug ineffective268
- hypertension259
- off label use231
- foetal growth restriction216
- pre-eclampsia208
- atrial septal defect196
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 71 |
| 2006 | 63 |
| 2007 | 60 |
| 2008 | 99 |
| 2009 | 127 |
| 2010 | 112 |
| 2011 | 161 |
| 2012 | 161 |
| 2013 | 166 |
| 2014 | 253 |
| 2015 | 198 |
| 2016 | 219 |
| 2017 | 245 |
| 2018 | 468 |
| 2019 | 431 |
| 2020 | 393 |
| 2021 | 346 |
| 2022 | 329 |
| 2023 | 257 |
| 2024 | 305 |
| 2025 | 199 |
| 2026 | 236 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis.
Hup RJ, Damen JAA, Terstappen J, et al. · Am J Obstet Gynecol 2025 · Network Meta-Analysis, Systematic Review
- Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.
Wang T, Jiang R, Yao Y, et al. · Hypertens Pregnancy 2024 · Systematic Review, Network Meta-Analysis
- Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.
Scott G, Gillon TE, Pels A, et al. · Am J Obstet Gynecol 2022 · Systematic Review
- Oslo Hypertension Study.
Leren P, Helgeland A · Drugs 1986 · Clinical Trial, Randomized Controlled Trial
- Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
van de Vusse D, Mian P, Schoenmakers S, et al. · Eur J Clin Pharmacol 2022 · Systematic Review
- Postpartum management of the hypertensive disorders of pregnancy: a systematic review and meta-analysis.
Tol ID, Khalil A, Cairns AE, et al. · Am J Obstet Gynecol 2026 · Systematic Review, Meta-Analysis
Sponsor: Chartwell Rx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.